12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Endometrial Regenerative Cells: Preliminary Phase II data

Preliminary data from the double-blind, placebo-controlled, Russian Phase II RECOVER-ERC trial showed that no treatment-related adverse events were reported in 17 evaluable patients treated with ERCs. The trial is evaluating...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >